Ramucirumab

證據等級: L5

預測適應症: 10 個

Ramucirumab: From Unspecified Original Oncology Indication to Uterine Ligament Adenocarcinoma

One-Sentence Summary

Ramucirumab is a VEGFR2-targeting monoclonal antibody; its original approved indication is not documented in this evidence pack. The TxGNN model predicts it may be effective for Uterine Ligament Adenocarcinoma (and 9 closely related rare gynecologic carcinoma subtypes), but there are currently 0 clinical trials and 0 publications supporting this specific direction — the prediction rests solely on network-based inference.

Quick Overview

Item	Content
Original Indication	Not documented in this evidence pack
Predicted New Indication	Uterine Ligament Adenocarcinoma
TxGNN Prediction Score	99.95%
Evidence Level	L5
US Market Status	Not Marketed
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is flagged as a data gap in this evidence pack (DG002, High severity). However, the repurposing rationale supplied with the prediction indicates that Ramucirumab is a VEGFR2 monoclonal antibody that inhibits tumor angiogenesis.

The original indication is not recorded here, so no direct comparison between the original and predicted indications can be made from this evidence pack alone. Mechanistically, the rationale draws an analogy to the “class effect” seen with other anti-angiogenic agents (e.g., bevacizumab in the GOG-240 trial) in gynecologic malignancies such as cervical cancer — suggesting that VEGFR2 blockade has a plausible theoretical basis across gynecologic adenocarcinoma subtypes. This is a mechanism-level inference, not a validated finding for Ramucirumab specifically.

All ten predicted indications in this evidence pack are rare cervical/uterine ligament carcinoma subtypes with near-identical TxGNN scores (~99.9%), and every one is explicitly noted as having no direct clinical or literature evidence — the mechanistic argument is theoretical only.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Additional Predicted Indications (Rank 2–10)

Rank	Disease	TxGNN Score
2	Endocervical carcinoma	99.95%
3	Adenoid cystic carcinoma of the cervix uteri	99.95%
4	Uterine ligament serous adenocarcinoma	99.94%
5	Signet ring cell variant cervical mucinous adenocarcinoma	99.94%
6	Cervical adenosquamous carcinoma, glassy cell variant	99.94%
7	Uterine ligament endometrioid adenocarcinoma	99.94%
8	Uterine ligament clear cell adenocarcinoma	99.94%
9	Uterine ligament mucinous adenocarcinoma	99.94%
10	Intestinal variant cervical mucinous adenocarcinoma	99.94%

All entries share the same evidence status: L5, S0, Hold — no clinical trials or literature identified for any of them.

Cytotoxicity

(Included because the drug targets VEGFR2 as an anti-angiogenic agent, and all predicted indications are carcinomas.)

Item	Content
Cytotoxicity Classification	Targeted therapy (VEGFR2-targeted anti-angiogenic monoclonal antibody)
Myelosuppression Risk	Please refer to the package insert warnings and precautions
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	Please refer to the package insert warnings and precautions
Handling Protection	Please refer to the package insert warnings and precautions

Safety Considerations

Please refer to the package insert for safety information.

(Note: TFDA/FDA label warnings and contraindications are flagged as a Blocking data gap — DG001 — in this evidence pack and could not be evaluated.)

Conclusion and Next Steps

Decision: Hold

Rationale: All ten predicted indications rely exclusively on TxGNN model output (L5) with zero supporting clinical trials or literature, and a Blocking data gap (missing label warnings/contraindications) prevents even initial safety screening.

To proceed, the following is needed:

TFDA/FDA package insert warnings and contraindications (DG001, Blocking)
Confirmed mechanism of action data from DrugBank (DG002, High)
Original approved indication(s) for baseline mechanistic comparison
Any preclinical or case-level evidence specific to Ramucirumab in gynecologic adenocarcinoma subtypes before advancing beyond S0
US market/licensing status verification, given the current record shows 0 licenses
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.